Abstract:Abstract Background Recurrence of cardiovascular (CV) events (CVe) and mortality are high after the index event. In the SECURE trial, CV Polypill Strategy (acetyl salicylic acid [ASA]+atorvastatin+ramipril) reduced CV mortality by 33% in post-acute myocardial infarction (AMI) patients over 3 years (median) compared to usual pharmacologic treatment. The 2023 ESC Guidelines recommend the CV Polypill to improve outcomes and adherence in secondary prevention after acute coronary syndrome, emphasizing early initiation for better patient prognosis post-discharge. Purpose To reach consensus among medical experts worldwide on the optimal utilisation of the CV Polypill Strategy (ASA+atorvastatin+ramipril) as baseline treatment to prevent recurrent CVe in routine clinical practice. Methods A two-round, modified Delphi method was used. A questionnaire with 30 evidence-based statements was created and validated by 8 renowned cardiologists. 50 clinicians from 19 countries in Europe, Latin America and Asia formed the Delphi panel. Panellists ranked their responses using a three-point Likert scale for agreement and importance. Consensus was reached when ≥80% agreed or deemed questions 'very important' or 'important' (Graph 1). Statements without consensus in the first round were refined based on evidence and participant feedback in the second round. Any remaining disagreements were resolved in a face-to-face meeting with the experts. Descriptive statistics were applied. Results Response rates were 76% and 74% in round 1 (March-April 2023) and round 2 (May-June 2023), respectively. Panellists were 82% cardiologists; 13% internists; 74% frequently advised the CV Polypill Strategy (ASA+atorvastatin+ramipril). 93.3% statements achieved consensus. 97.4% agreement on research findings indicating 24% relative risk reduction of CV death, AMI, stroke, or urgent revascularization over 3 years (median) with the CV Polypill Strategy, compared to usual care after a coronary heart disease event, expected to replicate in clinical practice. 100% accord on the CV Polypill Strategy implemented on hospital discharge or first follow-up visits as baseline therapy. 81.1% coincidence on its initiation as soon as symptoms stabilize. Agreement on following algorithms to start (97.3%) or switch (97.4%) to the CV Polypill Strategy from separate cardioprotective drugs. Agreement on CV Polypill Strategy in discharge plan for therapeutic goals (81.6%) and improved adherence (94.7%), and on hospital team’s awareness of CV Polypill Strategy’s CV benefits (100%). 97.4% accord on considering patients' preferences in the discharge plan. Agreement (89.5%) on the polypill strategy delivering cost savings over the patient's lifetime (Table 1). Conclusions Experienced clinicians strongly advocate early adoption of the CV Polypill Strategy (acetyl salicylic acid+atorvastatin+ramipril) to reduce recurrence, enhance prognosis, lower CV mortality, and potentially reduce lifetime costs after a CV event. Graph 1. Table 1

COST-EFFECTIVENESS OF POLYPILL TREATMENT IN HIGH-RISK HYPERTENSIVE SUBJECTS WITH HYPER-CHOLESTEROLAEMIA.

Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation

Role of polypill in cardiovascular prevention and treatment

COST-EFFECTIVENESS OF SINGLE-PILL AND SEPARATE-PILL ADMINISTRATION OF ANTIHYPERTENSIVE TRIPLE-COMBINATION THERAPY: A POPULATION-BASED MICROSIMULATION STUDY

Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

EFFECTIVENESS AND SAFETY OF NUTRACEUTICAL COMPOUNDS ADDED TO EZETIMIBE TREATMENT IN HYPERTENSIVE AND HYPER–CHOLESTEROLEMIC SUBJECTS WITH STATIN–INTOLERANCE

Polypill Strategy in Secondary Cardiovascular Prevention

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries

Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension

Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases

Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective

Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis

Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.

The CNIC polypill (Acetylsalicylic acid + Atorvastatin + Rampril) in secondary prevention of cardiovascular disease in patients with type 2 diabetes: A comparative analysis with alternative therapeutic approaches

A higher adherence to perindopril-based anti-hypertensive therapy is associated with a reduced risk of cardiovascular outcomes and all-cause mortality in real clinical practice in Italy

The CV polypill strategy (acetyl salicylic acid + atorvastatin + ramipril) as baseline treatment after a cardiovascular event supported by recent compelling evidence: a global expert consensus

Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial

Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial

Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis

Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study